|Articles|November 8, 2022

Cytel Acquires SDS Life Science and SDS MedteQ

Move will add new global talent to Cytel’s Strategic Consulting group.

Cytel has entered into an agreement to acquire SDS Life Science AB and SDS MedteQ AB. The move will add new global talent to Cytel’s Strategic Consulting group and bring additional capabilities for the strategic development of drugs and medical devices.

Read more about the acquistions here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
September 15th 2025
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
September 15th 2025
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
September 15th 2025
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
September 15th 2025
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025

Trending on Applied Clinical Trials Online

Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research

NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG

Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome

Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

© 2025 MJH Life Sciences^®

All rights reserved.